دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Sodium–glucose co-transporter inhibitors, iron therapy, and checkpoint inhibitors: new clinical and translational pieces of the heart failure puzzle
Filippo Crea
doi : 10.1093/eurheartj/ehab857
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4871–4875
How an ‘accidental doctor’ became a renowned cardiologist
Mark Nicholls
doi : 10.1093/eurheartj/ehab305
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4876–4877
Making connections to overcome arrhythmias
Mark Nicholls
doi : 10.1093/eurheartj/ehab311
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4878–4880
Leveraging non-coding RNAs to fight cardiovascular disease: the EU-CardioRNA network
Emma Louise Robinson, Costanza Emanueli, Fabio Martelli, Yvan Devaux
doi : 10.1093/eurheartj/ehab326
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4881–4883
Appointment as Board Reviewer: Ik-Kyung Jang, MD, PhD
Luca Liberale
doi : 10.1093/eurheartj/ehab322
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Page 4884
Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?
Massimo Volpe, Carlo Patrono
doi : 10.1093/eurheartj/ehab733
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4885–4886
Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations
Javed Butler, Stefan D Anker, Gerasimos Filippatos, Muhammad Shariq Usman, Joao Pedro Ferreira, Faiez Zannad, Milton Packer
doi : 10.1093/eurheartj/ehab704
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4887–4890
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Brendon L Neuen, Megumi Oshima, Vlado Perkovic, Rajiv Agarwal, Clare Arnott, George Bakris, Christopher P Cannon, David M Charytan, Robert Edwards, Jose L Górriz, Meg J Jardine, Adeera Levin, Bruce Neal, Luca De Nicola, Carol Pollock, Norman Rosenthal, David C Wheeler, Kenneth W Mahaffey, Hiddo J L Heerspink
doi : 10.1093/eurheartj/ehab497
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4891–4901
Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin–angiotensin–aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium?glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain.
SGLT2 inhibitors: the story continues to unfold
Ileana L Piña
doi : 10.1093/eurheartj/ehab561
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4902–4904
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial
Pieter Martens, Matthias Dupont, Jeroen Dauw, Petra Nijst, Lieven Herbots, Paul Dendale, Pieter Vandervoort, Liesbeth Bruckers, Wai Hong Wilson Tang, Wilfried Mullens
doi : 10.1093/eurheartj/ehab411
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4905–4914
Iron deficiency is common in heart failure with reduced ejection fraction (HFrEF) and negatively affects cardiac function and structure. The study the effect of ferric carboxymaltose (FCM) on cardiac reverse remodelling and contractile status in HFrEF.
Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?
Ewa A Jankowska, Piotr Ponikowski
doi : 10.1093/eurheartj/ehab624
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4915–4918
Prognostic value of comprehensive intracoronary physiology assessment early after heart transplantation
Jung-Min Ahn, Frederik M Zimmermann, Satish Arora, Ole-Geir Solberg, Oskar Angerås, Katrine Rolid, Muzammil Rafique, Lars Aaberge, Kristjan Karason, Kozo Okada, Helen Luikart, Kiran K Khush, Yasuhiro Honda, Nico H J Pijls, Sang Eun Lee, Jae-Joong Kim, Seung-Jung Park, Lars Gullestad, William F Fearon
doi : 10.1093/eurheartj/ehab568
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4918–4929
We evaluated the long-term prognostic value of invasively assessing coronary physiology after heart transplantation in a large multicentre registry.
Early diagnosis of cardiac allograft vasculopathy: biopsy, liquid biopsy, non-invasive imaging, coronary imaging, or coronary physiology?
Fernando Alfonso, Fernando Rivero, Javier Segovia-Cubero
doi : 10.1093/eurheartj/ehab722
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4930–4933
The Stanford experience of heart transplantation over five decades
Yuanjia Zhu, Bharathi Lingala, Michael Baiocchi, Veronica Toro Arana, Kiah M Williams, Yasuhiro Shudo, Philip E Oyer, Y Joseph Woo
doi : 10.1093/eurheartj/ehab416
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4934–4943
Since 1968, heart transplantation has become the definitive treatment for patients with end-stage heart failure. We aimed to summarize our experience in heart transplantation at Stanford University since the first transplantation performed over 50?years ago.
Improving survival after heart transplantation despite increasing complexity
Donna Mancini, Gregory T Gibson, Sabarivinoth Rangasamy
doi : 10.1093/eurheartj/ehab517
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4944–4946
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Hidekazu Kondo, Ioannis Akoumianakis, Ileana Badi, Nadia Akawi, Christos P Kotanidis, Murray Polkinghorne, Ilaria Stadiotti, Elena Sommariva, Alexios S Antonopoulos, Maria C Carena, Evangelos K Oikonomou, Elsa Mauricio Reus, Rana Sayeed, George Krasopoulos, Vivek Srivastava, Shakil Farid, Surawee Chuaiphichai, Cheerag Shirodaria, Keith M Channon, Barbara Casadei, Charalambos Antoniades
doi : 10.1093/eurheartj/ehab420
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4947–4960
Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects, on myocardial redox signalling in humans.
Canagliflozin and myocardial oxidative stress: SGLT1 inhibition takes centre stage
Gabriele G Schiattarella, David Bode
doi : 10.1093/eurheartj/ehab519
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4961–4963
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis
Charles Dolladille, Julia Akroun, Pierre-Marie Morice, Anne Dompmartin, Emilien Ezine, Marion Sassier, Angélique Da-Silva, Anne-Flore Plane, Damien Legallois, Jean-Mathieu L’Orphelin, Joachim Alexandre
doi : 10.1093/eurheartj/ehab618
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4964–4977
The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown.
Immune checkpoint inhibitors and cardiovascular events among patients with cancer: a window into the critical role of the immune system in cardiovascular biology
Lavanya Kondapalli, Tomas G Neilan
doi : 10.1093/eurheartj/ehab708
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4978–4980
Percutaneous intervention in patients with cancer: can we offer an improvement in safety?
Iñigo Lozano, Jose Miguel Vegas, Juan Rondan
doi : 10.1093/eurheartj/ehab401
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Page 4981
Decision making in percutaneous coronary intervention in patients with cancer: balancing ischaemic and bleeding risk
Mamas Andreas Mamas
doi : 10.1093/eurheartj/ehab403
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Pages 4982–4983
Para-aortic channel in congenital heart disease: computed tomography and transoesophageal echography depiction of an undescribed type of interatrial communication
Benjamin Mehier, Anne-Sophie Da Silva, Jean-Nicolas Dacher
doi : 10.1093/eurheartj/ehaa1072
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Page 4904
Spontaneous intramyocardial haemorrhage in a patient with wild-type transthyretin cardiac amyloidosis
Chuanfen Liu, Walter R T Witschey, Pasquale Santangeli, Yuchi Han
doi : 10.1093/eurheartj/ehaa1026
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Page 4929
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
Theresa A McDonagh, Marco Metra, Marianna Adamo, Roy S Gardner, Andreas Baumbach, Michael Böhm, Haran Burri, Javed Butler, Jelena ?elutkien?, Ovidiu Chioncel, John G F Cleland, Andrew J S Coats, Maria G Crespo-Leiro, Dimitrios Farmakis, Martine Gilard, Stephane Heymans, Arno W Hoes, Tiny Jaarsma, Ewa A Jankowska, Mitja Lainscak, Carolyn S P Lam, Alexander R Lyon, John J V McMurray, Alexandre Mebazaa, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Giuseppe M C Rosano, Frank Ruschitzka, Anne Kathrine Skibelund ESC Scientific Document Group
doi : 10.1093/eurheartj/ehab670
European Heart Journal, Volume 42, Issue 48, 21 December 2021, Page 4901
